

1 **Multidrug-resistant organism bloodstream infections in solid organ transplant recipients and**
2 **impact on mortality: a systematic review**

3

4 Alice Liu¹, Adelaide Dennis¹, Zarin Fariha¹, Rekha Pai Mangalore¹, Nenad Macetic^{*1,2,3}

5

6 **Affiliations**

7 ¹ Department of Infectious Diseases, The Alfred Hospital and School of Translational Medicine,
8 Monash University, Melbourne, Australia

9 ² Centre to Impact AMR, Monash University, Clayton, Australia

10 ³ Infection Prevention & Healthcare Epidemiology, Alfred Health, Melbourne, Australia.

11

12 * Corresponding Author

13 Dr. Nenad Macetic, Department of Infectious Diseases, The Alfred Hospital and School of
14 Translational Medicine, Monash University, Level 1 Alfred Lane House, Alfred Hospital, 55
15 Commercial Rd, Melbourne, VIC 3004, Australia. Email: nenad.macesic1@monash.edu

16

17 **Word count (excluding abstract): 2465**

18 **Abstract (280 words)**

19 *Background:* Bloodstream infections (BSI) cause significant morbidity and mortality in solid organ
20 transplant (SOT) recipients. There are few data regarding the contribution of multidrug-resistant
21 organisms (MDROs) to these infections.

22 *Objectives:* We evaluated the resistance-percentage of MDRO BSIs in SOT recipients and
23 assessed associated mortality.

24 *Methods:* A systematic review

25 *Data sources:* MEDLINE and Embase databases up to January 2024.

26 *Study eligibility criteria:* Studies of adult SOT recipients that quantify MDRO BSI resistance-
27 percentage and/or associated crude mortality. MDROs studied were carbapenem-resistant
28 Enterobacterales (CRE), *Acinetobacter baumannii* (CRAB) and *Pseudomonas aeruginosa* (CRPA),
29 third-generation-cephalosporin-resistant Enterobacterales (3GCR-E), methicillin-resistant
30 *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus faecium* (VRE).

31 *Participants:* Adult SOT recipients with a microbiologically confirmed BSI.

32 *Interventions:* Not applicable.

33 *Risk of bias assessment:* Newcastle Ottawa Scale.

34 *Methods of data synthesis:* MDRO BSI resistance-percentage and mortality outcomes were
35 reported as median (IQR) and crude mortality (%), respectively.

36 *Results:* Of 945 studies identified, 52 were included. Most were retrospective (41/52) and/or single
37 centre (37/52), and liver transplantation was the most studied SOT type (22/52). High resistance-
38 percentages of BSIs were noted, ranging from 13.6% CRE for Enterobacterales to 59.2% CRAB for
39 *Acinetobacter baumannii*. Resistance-percentage trends decreased over time, but these changes
40 were not statistically significant. Asia had highest resistance-percentages for MRSA (86.2% [IQR
41 77.3-94.6%]), 3GCR-E (59.5% [IQR 40.5-66.7%]) and CRE (35.7% [IQR 8.3-63.1%]). North America
42 had highest VRE resistance-percentages (77.7% [IQR 54.6-94.7%]). Crude mortality was 15.4-
43 82.4% and was consistently higher than non-MDRO BSIs.

44 *Conclusions:* MDRO BSIs resistance-percentages were high for all pathogens studied (IQR 24.6-
45 69.4%) but there was geographical and temporal heterogeneity. MDRO BSIs were associated with

46 high mortality in SOT recipients. Microbiological and clinical data in this vulnerable population were

47 incomplete, highlighting the need for robust international multi-centre studies.

48

49 **Introduction**

50 Solid organ transplantation (SOT) provides a life-saving measure for patients with end-stage organ
51 failure. However, SOT recipients are at increased susceptibility to infection, which may result in
52 impaired graft function and adverse outcomes (1). Bloodstream infections (BSI) are a leading cause
53 of morbidity and mortality in this population (2-5), with mortality reaching 50% when associated with
54 septic shock (5, 6). Post-transplant BSIs result in prolonged hospital stays, need for re-admission
55 and substantial financial costs (4). Infections with multidrug-resistant organisms (MDROs) are
56 common among SOT recipients due to extended exposure to broad spectrum antimicrobials,
57 immunosuppressive medications, presence of chronic indwelling devices and frequent healthcare
58 exposure (7, 8). SOT itself has been described as an independent risk factor for certain MDRO
59 infections (8). MDRO infections are associated with greater mortality and increased risk of graft
60 failure than those caused by susceptible pathogens (7, 9, 10), posing a major challenge to individual
61 patient care. Furthermore, antimicrobial treatment options for these organisms are often limited and
62 may come with significant toxicities and cost.

63

64 While there are multiple reports of high resistance rates and poor outcomes of BSIs in SOT
65 recipients (7, 11-13), there remains an urgent need to better understand the epidemiology and
66 temporal trends in these infections. In the absence of prior systematic review data, we provide a
67 comprehensive description of MDRO BSI resistance-percentages and associated mortality in SOT
68 recipients, focusing on clinically relevant pathogens that influence empirical and directed
69 antimicrobial decision making. The MDROs studied in this review represent a critical group of
70 pathogens that pose a significant global public health threat and are common causes of life-
71 threatening hospital-acquired infection (14).

72

73 **Methods**

74 Study selection

75 We performed a systematic review of all published literature describing resistance-percentage
76 and/or mortality of BSIs due to MDROs among adult SOT recipients. Six MDROs were selected

77 from the WHO Bacterial Priority Pathogens (2024 update) due to their relevance for SOT recipients
78 (15): carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant *Acinetobacter*
79 *baumannii* (CRAB), carbapenem-resistant *Pseudomonas aeruginosa* (CRPA), third generation
80 cephalosporin-resistant Enterobacterales (3GCR-E), vancomycin-resistant *Enterococcus faecium*
81 (VRE) and methicillin-resistant *Staphylococcus aureus* (MRSA).

82

83 We included all published studies (retrospective and prospective) of adult (≥ 18 years) SOT
84 recipients (heart, lung, liver, kidney, pancreas, intestinal and multivisceral) that quantified BSIs due
85 to MDROs and/or associated crude mortality rates. Additional studies were identified from review of
86 reference lists. Only full text studies were included in the analysis. Case reports, expert opinion
87 pieces, narrative reviews, pharmacokinetic/pharmacodynamic studies, and studies of colonisation or
88 surveillance blood cultures were excluded. Studies that lacked quantitative data of the proportion of
89 BSIs due to MDROs were also omitted.

90

91 The primary outcome was proportion of BSIs due to MDROs, expressed as median [IQR]. The
92 secondary outcome was crude mortality due to MDRO BSI, expressed as a proportion (%).

93

94 Search strategy

95 A literature search was conducted in the Embase and MEDLINE databases in accordance with
96 guidelines from the Preferred Reporting Items for Systematic Reviews and Meta
97 Analyses (PRISMA) statement (16). No time or language restriction was applied. The following key
98 words and their related MeSH and Emtree search terms were used in various combinations:
99 bloodstream infection, bacteraemia, sepsis, solid organ transplantation, organ graft, multidrug-
100 resistant organism, antimicrobial resistance, carbapenem resistance, extended-spectrum beta-
101 lactamase, vancomycin resistance, methicillin resistance, Enterobacterales, Acinetobacter,
102 Pseudomonas, Staphylococcus and Enterococcus. Full search strategy results are provided in
103 Supp. Tables 1 and 2. The study was registered with PROSPERO (CRD42023466931).

104

105 Data extraction and analysis

106 Title and abstract screening were performed by AL. Full text screening was performed by three
107 reviewers (AL, AD, ZF), who also extracted data independently. Conflicts between reviewers on
108 eligibility assessments and data extraction results were resolved through discussion and consensus
109 among all authors. Duplicate studies were removed via Covidence systematic review software
110 (Veritas Health Innovation, Melbourne, Australia) and manual checking. Data were extracted using a
111 custom extraction template covering the following variables: study design, year and location, study
112 population size, type/s of transplant, MDRO species and their frequency, associated crude mortality
113 (where available) and antimicrobial susceptibility testing methods. Statistical analyses and
114 visualisations were performed with R v4.3.0 (2023). Specifically, we applied a linear regression
115 analysis using the 'lm' function to assess the presence of a trend in MDRO resistance-percentages
116 over time.

117

118 Risk of bias assessment

119 Quality assessment was conducted using the Newcastle Ottawa Scale (NOS) (17). For the NOS
120 assessment, exposure was defined as BSI due to MDRO. Comparability of cohorts was based on
121 controlling for baseline patient demographics and immunosuppression regimen. Assessment of
122 MDRO proportions was through microbiological confirmation with a description of the antimicrobial
123 susceptibility methods included. Assessment of mortality outcomes was through an independent
124 assessment or record linkage. There was no minimum follow-up period, and the shortest study
125 period was 12 months (18). Studies with a NOS score of 7 or greater were included in the final
126 analysis.

127

128 **Results**

129 Study characteristics

130 A total of 1137 studies were identified. After removal of duplicates, 945 were screened, of which 114
131 studies were retrieved and 52 included in the final analysis (Fig. 1). Reasons for exclusion (62
132 studies) were incorrect study design, outcomes not specific to BSIs or insufficient data on
133 antimicrobial susceptibility. Most studies were retrospective (41/52, 78.8%) and single-centre (37/52,
134 71.2%). Of the studies focused on a single transplant type, liver transplant was the most studied
135 (22/52, 42.3%), followed by kidney transplant (5/52, 9.6%). Eighteen (34.6%) studies included
136 pooled multiple transplant types in their analysis. Study population size was variable, ranging from
137 14 BSI episodes over a 3-year period (19) to 988 episodes over 10 years (8). Full details on the
138 characteristics of the included studies are provided in Supp. Table 3. Quality assessment using the
139 NOS is described in Supp. Tables 4 and 5.

140

141 Pooled estimates of MDRO BSIs in SOT recipients

142 Proportion of BSIs due to MDROs was reported in 49/52 studies with only crude mortality reported
143 in the remaining three studies. MDRO BSI resistance-percentages are shown in Table 1 and Fig. 2A
144 and ranged from 13.6% (IQR 8.7-37.0%) carbapenem resistance in Enterobacterales to 59.2% (IQR
145 50.0-77.4%) carbapenem resistance in *Acinetobacter baumannii*. We analysed MDRO resistance-
146 percentages over time and noted reducing trends for all MDROs except CRAB, but these changes
147 were not statistically significant (Table 1, Fig. 2B and Supp. Table 6).

148

149 MDRO BSI resistance-percentage varied by region (Table 1), with Asia having highest median
150 resistance-percentages of MRSA (86% [IQR 77-95%]), 3GCR-E (60% [IQR 40-67%]), CRE (36%
151 [IQR 8-63%]) and CRAB (60% [IQR 54-89%]). North America had highest VRE resistance-
152 percentages (median 78% [IQR 55-95%]). South America had highest CRPA resistance-percentage
153 (88%), but this was based on results of a single study.

154

155 Liver transplantation was the most studied transplant type with the following median MDRO
156 resistance-percentages: CRE 9.5% (IQR 4.7-14.3%), 3GCR-E 40.4% (IQR 26.7-59.5%), CRAB
157 72.3% (IQR 48.2-93.3%), CRPA 33.3% (IQR 9.1-5.7%), VRE 34.0% (IQR 24.3-69.8%) and MRSA
158 80.0% (IQR 48.7-96.4%). Kidney transplantation had sufficient data for analysis of 3GCR-E
159 resistance-percentage (median 32.4% [IQR 21.1-65.3%]), but there were too few studies to
160 determine these for other transplant type/MDRO combinations.

161

162 Pooled estimates of mortality due to MDRO BSI in SOT recipients

163 Mortality associated with MDRO BSI was reported in 17/52 (32.7%) studies (Table 2). The method
164 of reporting varied between studies, including different time intervals. In most studies (13/17, 76.5%)
165 mortality was recorded by attributable organism, however 3 studies pooled multiple MDRO
166 pathogens for mortality outcomes. Within these limits, crude mortality due to MDRO BSI ranged
167 from 15.4% (VRE 30-day mortality in liver transplant recipients) (20) to 82.4% (CRE mortality in liver
168 transplant recipients admitted to intensive care) (21). Excluding patients in the intensive care
169 setting, crude mortality remained as high as 65.5% (CRAB 10- and 30-day mortality in liver
170 transplant recipients) (22). Where mortality due to MDRO BSI was assessed alongside drug-
171 susceptible BSI, MDRO BSIs were consistently associated with a higher mortality rate irrespective
172 of MDRO or transplant type (Table 2). For individual MDROs, MRSA and VRE-associated mortality
173 were most frequently reported, with a median crude mortality of 36.1% (IQR 19.3–56.3%) and
174 37.2% (IQR 30.9-42.5%), respectively. There was insufficient data for pooled analysis for all other
175 MDROs studied.

176

177 **Discussion**

178 Our systematic review aimed to quantify the burden of MDRO BSIs in SOT recipients and
179 successfully consolidated global antimicrobial resistance (AMR) data for multiple clinically relevant
180 pathogens that cause BSIs in SOT recipients. We observed high resistance-percentages for BSIs in
181 SOT recipients, ranging from median 13.6% for CRE BSIs to median 56.2% for CRAB BSIs.

182 However, there was considerable heterogeneity in resistance-percentages across different regions
183 and time periods. While there were decreasing trends in MDRO BSIs over time, CRAB remained an
184 exception. MDRO BSIs were associated with high crude mortality in SOT recipients, ranging from
185 15% up to 82.4% in one study in an intensive care setting (21).

186

187 We noted prominent differences in MDRO BSI burden across regions. A key question arises
188 regarding comparison with AMR burden in the general population. Asia had highest resistance-
189 percentages for multiple pathogens (MRSA, 3GCR-E, CRE and CRAB). These were higher than in
190 the general hospitalised population in Asia (30.5-49.0% for MRSA BSIs, 36.0-57.2% for 3GCR-E
191 BSIs and 23.1-26.1% for CRE BSIs) (23, 24) but lower for CRAB BSIs (median 60% in SOT
192 recipients vs. 71.5-90.5%) (23, 24). Most Asian studies were confined to liver transplant, which is
193 more commonly associated with post-operative bacterial infections (25-27). This, combined with
194 high overall rates of AMR in many Asian countries may explain the high resistance-percentages for
195 BSIs in SOT recipients we observed in this region (23, 28, 29). North America exhibited the highest
196 resistance percentage of VRE (median 76.6%), aligning with surveillance data demonstrating >70%
197 of US hospital *Enterococcus faecium* isolates are VRE (30). Conversely, Europe had the lowest
198 VRE resistance-percentages (median 3.0%). European general VRE surveillance data range widely
199 from <1% in Holland to 45% in Greece (31). In our review, Spanish (4/16, 25%) and Italian studies
200 (4/16, 25%) were most frequently represented, and our VRE findings reflected surveillance data
201 rates from both countries (3% and 11%, respectively) (31).

202

203 Resistance-percentages decreased over time for several of the pathogens studied (MRSA, VRE,
204 3GCR-E, CRE and CRPA). While these trends did not reach statistical significance, this finding
205 contrasts to global observations of increasing MDRO prevalence over time (32-35). MRSA is unique
206 in demonstrating an early rise and subsequent fall in its prevalence across multiple geographic
207 regions over the last two decades (36), potentially explaining our findings of reducing MRSA trends.
208 The decreasing prevalence of other MDROs over time may potentially be attributed to
209 improvements in infection control measures, better detection of donor-derived infections and

210 changes in antibiotic prophylaxis prescribing practices over time (37, 38). Furthermore, global AMR
211 surveillance methods are not standardised nor is coverage universal (39), and the resistance-
212 percentage rates noted in this study represent specialised transplant centres rather than all
213 healthcare facilities. In contrast, we noted increasing CRAB resistance-percentages in our study,
214 which may reflect the contribution of frequent intensive care unit admission following SOT, with
215 healthcare-associated horizontal transmission of CRAB well described in this setting (40, 41).

216

217 We found high crude mortality rates among patients with MDRO BSIs ranging from 15.4 to 82.4%.
218 However, this was based on limited data (17 studies), with almost all studies reporting on <100 SOT
219 recipients with MDRO BSI. These findings contrast with prior reports that noted lower mortality in
220 SOT recipients with sepsis in the early post-transplant period than in non-SOT patients (42, 43).
221 However, these studies did not distinguish between BSI with susceptible and drug-resistant
222 pathogens. Even fewer studies (n=4) compared mortality between MDRO and non-MDRO BSIs in
223 SOT recipients, but in these studies MDRO BSIs were consistently associated with a higher crude
224 mortality rate (10, 20, 44, 45). This may reflect use of empiric antibiotics with inadequate spectra of
225 activity. Alterations in the pathophysiology of different SOT recipients may also account for the high
226 overall mortality rate in this population. For example, heart transplant recipients have higher risk of
227 cardiogenic shock complicating septic shock, while lung transplant recipients are at greater risk of
228 respiratory failure requiring intubation and intensive care support (46).

229

230 Our study has several limitations. Firstly, the included studies were heterogeneous in their
231 population size and follow-up period. It was therefore not feasible to conduct a meta-analysis of the
232 study outcomes. The transplant type strongly influences the primary site of infection and associated
233 sepsis (47). We were unable to stratify MDRO frequency-percentages by transplant type because
234 many studies pooled multiple transplant types in their analyses. Additionally, data on prescribing
235 practices were inconsistently recorded across studies and there is a high likelihood that there were
236 geographical and temporal differences in therapeutic and prophylactic antimicrobial prescribing and
237 immunosuppression regimens. These differences would influence MDRO BSI frequency-

238 percentages observed. Finally, mortality data were not reported in a standardised manner, varying
239 from 5-day to 1-year mortality figures, limiting pooled analysis and comparison between studies.

240

241 Our review underscores several priorities in the care of SOT recipients. Our findings of high
242 resistance-percentages for BSIs and significant associated mortality highlight that prevention of
243 MDRO acquisition remains paramount. This includes but is not limited to proactive antimicrobial
244 stewardship pre- and post-transplantation to reduce selection pressure, infection control measures
245 to limit cross-transmission in hospital settings, and regular review of immunosuppressant
246 medications and indwelling devices to reduce the risk of colonisation. Strategies for early
247 identification of BSIs caused by MDROs may also help in timely antibiotic rationalisation and limiting
248 the emergence of MDROs in the transplant population, such as continued development of rapid
249 laboratory diagnostics and antimicrobial susceptibility testing methods, and implementation of
250 protocolised surveillance testing programs for donors and recipients.

251

252 We also identified future research priorities. Our review found a paucity of transplant type-specific
253 microbiological data, non-standardised mortality reporting methods and a reliance on retrospective
254 and/or single centre data resulting in wide variation in study size. It has been noted that frequency
255 measures such as resistance-percentages are of limited use without accompanying population
256 resistance-percentage estimates or incidence-density data (48), which was also evident in our
257 review. Future work should focus on longitudinal prospective data collection using consistent
258 metrics, capturing both clinical and microbiological outcomes and representing SOT types
259 proportionately. This presents an opportunity to further develop and implement larger scale
260 transplant registries such as the Swiss Transplant Cohort study (11, 13) which capture infectious
261 complications and corresponding microbiological data.

262

263 **Conclusion**

264 Our findings reinforce that SOT recipients are highly vulnerable to MDRO BSIs and experience
265 substantial associated mortality. We identified marked geographical variation in the proportion of

266 MDRO BSIs, which warrants ongoing characterisation in future studies. While there was a trend
267 towards reducing resistance-percentages of several MDROs, this was not statistically significant
268 and certain pathogens were under-represented. We noted gaps in the reporting of transplant type-
269 specific data and a paucity of standardised mortality outcomes. Our study highlights the urgent need
270 for robust international multi-centre cohort studies that adequately capture microbiological data and
271 BSI clinical outcomes to guide prevention and empirical treatment strategies in this highly
272 vulnerable patient group.

273

274 **Transparency declarations**

275 None to declare

276

277 **Funding**

278 This work was supported by the National Health and Medical Research Council of Australia
279 (Emerging Leader 1 Fellowship APP1176324 to N.M.).

280 The funders had no role in study design, data collection and interpretation, or the decision to submit
281 the work for publication.

282

283 References

- 284 1. Fishman JA. Infection in solid-organ transplant recipients. *N Engl J Med*. 2007;357(25):2601-
285 14.
- 286 2. Adelman MW, Connor AA, Hsu E, Saharia A, Mobley CM, Victor DW, 3rd, et al. Bloodstream
287 infections after solid organ transplantation: clinical epidemiology and antimicrobial resistance (2016-
288 21). *JAC Antimicrob Resist*. 2024;6(1):dlad158.
- 289 3. Gavalda J, Aguado JM, Manuel O, Grossi P, Hirsch HH, Hosts ESGoliC. A special issue on
290 infections in solid organ transplant recipients. *Clin Microbiol Infect*. 2014;20 Suppl 7:1-3.
- 291 4. Kritikos A, Manuel O. Bloodstream infections after solid-organ transplantation. *Virulence*.
292 2016;7(3):329-40.
- 293 5. Candel FJ, Grima E, Matesanz M, Cervera C, Soto G, Almela M, et al. Bacteremia and
294 septic shock after solid-organ transplantation. *Transplant Proc*. 2005;37(9):4097-9.
- 295 6. Moreno A, Cervera C, Gavalda J, Rovira M, de la Camara R, Jarque I, et al. Bloodstream
296 infections among transplant recipients: results of a nationwide surveillance in Spain. *Am J*
297 *Transplant*. 2007;7(11):2579-86.
- 298 7. Adelman MW, Connor AA, Hsu E, Saharia A, Mobley CM, Victor DW, III, et al. Bloodstream
299 infections after solid organ transplantation: clinical epidemiology and antimicrobial resistance
300 (2016–21). *JAC-Antimicrobial Resistance*. 2024;6(1).
- 301 8. Anesi JA, Lautenbach E, Tamma PD, Thom KA, Blumberg EA, Alby K, et al. Risk Factors for
302 Extended-Spectrum beta-lactamase-Producing Enterobacterales Bloodstream Infection Among
303 Solid-Organ Transplant Recipients. *Clin Infect Dis*. 2021;72(6):953-60.
- 304 9. Kadri SS, Lai YLE, Ricotta EE, Strich JR, Babiker A, Rhee C, et al. External Validation of
305 Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infection
306 Using Electronic Health Record Data From 140 US Hospitals. *Open Forum Infect Dis*.
307 2019;6(4):ofz110.
- 308 10. Anesi JA, Lautenbach E, Thom KA, Tamma PD, Blumberg EA, Alby K, et al. Clinical
309 Outcomes and Risk Factors for Carbapenem-resistant Enterobacterales Bloodstream Infection in
310 Solid Organ Transplant Recipients. *Transplantation*. 2023;107(1):254-63.
- 311 11. van Delden C, Stampf S, Hirsch HH, Manuel O, Meylan P, Cusini A, et al. Burden and
312 Timeline of Infectious Diseases in the First Year After Solid Organ Transplantation in the Swiss
313 Transplant Cohort Study. *Clin Infect Dis*. 2020;71(7):e159-e69.
- 314 12. Ye QF, Zhao J, Wan QQ, Qiao BB, Zhou JD. Frequency and clinical outcomes of ESKAPE
315 bacteremia in solid organ transplantation and the risk factors for mortality. *Transpl Infect Dis*.
316 2014;16(5):767-74.
- 317 13. Neofytos D, Stampf S, Hoessly LD, D'Asaro M, Tang GN, Boggian K, et al. Bacteremia
318 During the First Year After Solid Organ Transplantation: An Epidemiological Update. *Open Forum*
319 *Infect Dis*. 2023;10(6):ofad247.
- 320 14. Parker MT, Organization WH. Hospital-acquired infections: guidelines to laboratory methods:
321 World Health Organization. Regional Office for Europe; 1978.
- 322 15. WHO. WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health
323 importance to guide research, development and strategies to prevent and control antimicrobial
324 resistance. Geneva; 2024.
- 325 16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
326 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Bmj*.
327 2021;372:n71.
- 328 17. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa
329 Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Available from:
330 http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm].
- 331 18. Gagliotti C, Morsillo F, Moro ML, Masiero L, Procaccio F, Vespasiano F, et al. Infections in
332 liver and lung transplant recipients: a national prospective cohort. *Eur J Clin Microbiol Infect Dis*.
333 2018;37(3):399-407.
- 334 19. Karruli A, de Cristofaro J, Andini R, Iossa D, Bernardo M, Amarelli C, et al. Risk Factors and
335 Outcome of Multidrug-Resistant Infections after Heart Transplant: A Contemporary Single Center
336 Experience. *Microorganisms*. 2021;9(6).

- 337 20. Dubler S, Lenz M, Zimmermann S, Richter DC, Weiss KH, Mehrabi A, et al. Does
338 vancomycin resistance increase mortality in *Enterococcus faecium* bacteraemia after orthotopic liver
339 transplantation? A retrospective study. *Antimicrob Resist Infect Control*. 2020;9(1):22.
- 340 21. Mouloudi E, Massa E, Papadopoulos S, Iosifidis E, Roilides I, Theodoridou T, et al.
341 Bloodstream infections caused by carbapenemase-producing *Klebsiella pneumoniae* among
342 intensive care unit patients after orthotopic liver transplantation: risk factors for infection and impact
343 of resistance on outcomes. *Transplant Proc*. 2014;46(9):3216-8.
- 344 22. Min EK, Yim SH, Choi MC, Lee JG, Joo DJ, Kim MS, et al. Incidence, mortality, and risk
345 factors associated with carbapenem-resistant *Acinetobacter baumannii* bacteremia within 30 days
346 after liver transplantation. *Clin Transplant*. 2023;37(5):e14956.
- 347 23. Yang W, Ding L, Han R, Yin D, Wu S, Yang Y, et al. Current status and trends of
348 antimicrobial resistance among clinical isolates in China: a retrospective study of CHINET from
349 2018 to 2022. *One Health Advances*. 2023;1(1):8.
- 350 24. Kim D, Yoon EJ, Hong JS, Choi MH, Kim HS, Kim YR, et al. Major Bloodstream Infection-
351 Causing Bacterial Pathogens and Their Antimicrobial Resistance in South Korea, 2017-2019: Phase
352 I Report From Kor-GLASS. *Front Microbiol*. 2021;12:799084.
- 353 25. Kim SI. Bacterial infection after liver transplantation. *World J Gastroenterol*.
354 2014;20(20):6211-20.
- 355 26. Kim SH, Mun SJ, Ko JH, Huh K, Cho SY, Kang CI, et al. Poor outcomes of early recurrent
356 post-transplant bloodstream infection in living-donor liver transplant recipients. *Eur J Clin Microbiol
357 Infect Dis*. 2021;40(4):771-8.
- 358 27. Kim YJ, Kim SI, Wie SH, Kim YR, Hur JA, Choi JY, et al. Infectious complications in living-
359 donor liver transplant recipients: a 9-year single-center experience. *Transpl Infect Dis*.
360 2008;10(5):316-24.
- 361 28. Qiao M, Ying GG, Singer AC, Zhu YG. Review of antibiotic resistance in China and its
362 environment. *Environ Int*. 2018;110:160-72.
- 363 29. Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia. *Int J Antimicrob Agents*.
364 2011;37(4):291-5.
- 365 30. CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department
366 of Health and Human Services, CDC; 2019.
- 367 31. Werner G, Coque TM, Hammerum AM, Hope R, Hryniewicz W, Johnson A, et al. Emergence
368 and spread of vancomycin resistance among enterococci in Europe. *Eurosurveillance*.
369 2008;13(47):19046.
- 370 32. Ma J, Song X, Li M, Yu Z, Cheng W, Yu Z, et al. Global spread of carbapenem-resistant
371 Enterobacteriaceae: Epidemiological features, resistance mechanisms, detection and therapy.
372 *Microbiol Res*. 2023;266:127249.
- 373 33. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing
374 Enterobacteriaceae in Europe. *Euro Surveill*. 2008;13(47):19044.
- 375 34. Proportion of bloodstream infection due to methicillin-resistant *Staphylococcus aureus*
376 (MRSA) (%) [Internet]. WHO. 2024. Available from: <https://data.who.int/indicators/i/5dd9606>.
- 377 35. Bezabih YM, Bezabih A, Dion M, Batard E, Tekla S, Obole A, et al. Comparison of the global
378 prevalence and trend of human intestinal carriage of ESBL-producing *Escherichia coli* between
379 healthcare and community settings: a systematic review and meta-analysis. *JAC Antimicrob Resist*.
380 2022;4(3):dlac048.
- 381 36. Diekema DJ, Pfaller MA, Shortridge D, Zervos M, Jones RN. Twenty-Year Trends in
382 Antimicrobial Susceptibilities Among *Staphylococcus aureus* From the SENTRY Antimicrobial
383 Surveillance Program. *Open Forum Infect Dis*. 2019;6(Suppl 1):S47-s53.
- 384 37. Smibert O, Satlin MJ, Nellore A, Peleg AY. Carbapenem-Resistant Enterobacteriaceae in
385 Solid Organ Transplantation: Management Principles. *Curr Infect Dis Rep*. 2019;21(7):26.
- 386 38. Nellore A, Huprikar S, Practice AICo. Vancomycin-resistant *Enterococcus* in solid organ
387 transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases
388 Community of Practice. *Clin Transplant*. 2019;33(9):e13549.
- 389 39. WHO. Antimicrobial resistance: global report on surveillance. Geneva: WHO; 2014.
- 390 40. Jiang Y, Ding Y, Wei Y, Jian C, Liu J, Zeng Z. Carbapenem-resistant *Acinetobacter*
391 *baumannii*: A challenge in the intensive care unit. *Front Microbiol*. 2022;13:1045206.

- 392 41. Doughty EL, Liu H, Moran RA, Hua X, Ba X, Guo F, et al. Endemicity and diversification of
393 carbapenem-resistant *Acinetobacter baumannii* in an intensive care unit. *Lancet Reg Health West*
394 *Pac.* 2023;37:100780.
- 395 42. Donnelly JP, Locke JE, MacLennan PA, McGwin G, Jr., Mannon RB, Safford MM, et al.
396 Inpatient Mortality Among Solid Organ Transplant Recipients Hospitalized for Sepsis and Severe
397 Sepsis. *Clin Infect Dis.* 2016;63(2):186-94.
- 398 43. Kalil AC, Syed A, Rupp ME, Chambers H, Vargas L, Maskin A, et al. Is bacteremic sepsis
399 associated with higher mortality in transplant recipients than in nontransplant patients? A matched
400 case-control propensity-adjusted study. *Clin Infect Dis.* 2015;60(2):216-22.
- 401 44. Bodro M, Sabe N, Tubau F, Llado L, Baliellas C, Roca J, et al. Risk factors and outcomes of
402 bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients.
403 *Transplantation.* 2013;96(9):843-9.
- 404 45. Ye QF, Zhou W, Wan QQ. Donor-derived infections among Chinese donation after cardiac
405 death liver recipients. *World J Gastroenterol.* 2017;23(31):5809-16.
- 406 46. Eichenberger EM, Ruffin F, Sharma-Kuinkel B, Dagher M, Park L, Kohler C, et al. Bacterial
407 genotype and clinical outcomes in solid organ transplant recipients with *Staphylococcus aureus*
408 bacteremia. *Transpl Infect Dis.* 2021;23(6):e13730.
- 409 47. Linares L, Garcia-Goez JF, Cervera C, Almela M, Sanclemente G, Cofan F, et al. Early
410 bacteremia after solid organ transplantation. *Transplant Proc.* 2009;41(6):2262-4.
- 411 48. Pezzani MD, Arieti F, Rajendran NB, Barana B, Cappelli E, De Rui ME, et al. Frequency of
412 bloodstream infections caused by six key antibiotic-resistant pathogens for prioritization of research
413 and discovery of new therapies in Europe: a systematic review. *Clin Microbiol Infect.* 2024;30 Suppl
414 1:S4-S13.
- 415

416 **Fig. 1: PRISMA flow diagram**

417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447





Fig. 2: Comparison of proportions of bloodstream infections caused by multidrug-resistant organisms in solid organ transplant recipients by included study



Abbreviations: 3GCR-E – Third-generation cephalosporin-resistant Enterobacterales; CRAB – carbapenem-resistant *Acinetobacter baumannii*; CRE – carbapenem-resistant Enterobacterales; CRP – carbapenem-resistant *Pseudomonas aeruginosa*; MRSA –methicillin-resistant *Staphylococcus aureus*; VRE – vancomycin-resistant *Enterococcus*.

Table 1: Proportions of bloodstream infections caused by resistant organisms in solid-organ transplant recipients by time period and region

	Pooled (n = 49)	2002 – 2010 (n = 10)	2011 – 2015 (n = 15)	2016 – 2020 (n = 12)	2021 – 2024 (n = 12)	Europe (n = 16)	North America (n = 12)	South America (n = 4)	Asia (n = 17)
3GCR-E, median (IQR) (% of Enterobacterales)	38.2% (27–49%)	42.3% (33.6–50.9%)	30.0% (27.6–56.5%)	33.8% (20.8–40.8%)	40.0% (35.0–47.5%)	29.3% (21.2–40.5%)	33.5% (30.4–36.2%)	43.4% (41.9–44.9%)	63.1% (45.2–72.9%)
CRE, median (IQR) (% of Enterobacterales)	13.6% (8.7–37.0%)	9.5%*	45.5%*	28.6% (14.3–61.9%)	6.3% (3.6–9.1%)	14.3%*	12.9% (7.8–13.6%)	NR	35.7% (8.3–63.1%)
CRAB, median (IQR) (% of <i>A. baumannii</i>)	59.2% (50.0–77.4%)	60.0%*	54.2% (48.2–73.3%)	72.4% (6.2–83.6%)	84.6%*	50.0% (50.0–61.4%)	NR	53.6% (42.9–64.3%)	60.0% (54.2–88.7%)
CRPA, median (IQR) (% of <i>P. aeruginosa</i>)	33.3% (24.3–43.8%)	NR	33.3% (33.3–74.3%)	32.4% (27.9–36.8%)	17.0% (6.8–29.9%)	45.2% (25.0–61.4%)	38.9% (36.1–41.7%)	87.5*	27.5% (21.0–32.8%)
MRSA, median (IQR) (% of <i>S. aureus</i>)	50.4% (36.4–86.7%)	77.8% (47.40–100%)	56.0% (35.5–84.3%)	77.9% (73.9–81.8%)	31.5% (15.6–47.4%)	31.7% (22.0–46.6%)	50.5% (38.1–77.8%)	64.3% (53.6–75.0%)	86.2% (77.3–94.6%)
VRE, median (IQR) (% of <i>E. faecium</i>)	38.1% (3.0–67.6%)	55.6% (27.88–77.8%)	15.0% (0.0–36.1%)	53.0% (28.4–76.0%)	36.9% (8.9–62.2%)	3.0% (0.0–23.5%)	76.6% (57.2–89.4%)	38.6%*	32.3% (6.6–51.2%)

*only single studies available, unable to calculate IQR. NR = not reported.

Abbreviations: 3GCR-E – Third-generation cephalosporin-resistant Enterobacterales; CRAB – carbapenem-resistant *Acinetobacter baumannii*; CRE – carbapenem-resistant Enterobacterales; CRP – carbapenem-resistant *Pseudomonas aeruginosa*; MRSA – methicillin-resistant *Staphylococcus aureus*; VRE – vancomycin-resistant *Enterococcus*.

Table 2: Mortality due to bloodstream infection from multidrug resistant organism/s in solid organ transplant recipients:

Author	Year	Location	Study characteristics	Study population characteristics including SOT type	Organism/s studied	Mortality
Singh et al.	2004	United States	Retrospective, single centre, observational study	233 liver transplant recipients between 1989 – 2003	MRSA VRE	MRSA mortality 9/33 (27.3%) VRE mortality 4/8 (50.0%)
Husain et al.	2006	United States	Prospective, multicentre, observational study (4 sites)	56 lung transplant recipients with bacteraemia between July 2000 – February 2004	MRSA	MRSA mortality 1/6 (16.7%)
Bedini et al.	2007	Italy	Retrospective, single centre, observational study	205 liver transplant recipients between October 2000 - September 2005	MRSA	MRSA 30-day mortality 3/5 (60.0%)
Kim et al.	2009	Korea	Retrospective, single centre, observational study	144 liver transplant recipients between January 2005 – September 2007	MRSA VRE ESBL CRAB CRPA	VRE mortality 2/5 (40.0%)
Bodro et al.	2013	Spain	Prospective, single centre, observational study	190 SOT recipients (liver, kidney and heart) between January 2007 – December 2012	MRSA VRE 3GCR-E CRAB CRPA	Pooled MDRO mortality 19/54 (35.2%) Pooled non-MDRO mortality 32/185 (14.4%)
Aguiar et al.	2014	Brazil	Retrospective, single centre, observational study	759 kidney and 258 liver transplant recipients between January 2000 – September 2008	3GCR-E	ESBL 30-day mortality 10/39 (25.6%)

Mouloudi et al.	2014	Greece	Prospective, single centre, observational study	17 Liver transplant recipients admitted to the intensive care unit between January 2008 – December 2011	CRE (CRKP only)	CRKP mortality 14/17 (82.4%)
Ye et al.	2014	China	Retrospective, multicentre, observational study (2 sites)	71 SOT recipients between January 2002 – August 2013	MRSA VRE 3GCR-E CRE CRAB	Pooled MDRO 30-day mortality 22/39 (56.4%) Pooled non-MDRO 30-day mortality 12/32 (37.5%)
Zhou et al.	2015	China	Retrospective, multicentre, observational study (2 sites)	275 liver transplant recipients with <i>S. aureus</i> BSI between January 2001 – December 2014	MRSA	MRSA mortality 9/20 (45.0%)
Kim et al.	2018	Korea	Retrospective, single centre, observational study	393 liver transplant recipients from January 2008 – April 2015	CRAB	CRAB 1-year mortality 5/14 (35.7%)
Kim et al.	2019	Korea	Retrospective, single centre, observational study	536 liver transplant recipients between January 2008 – December 2017	VRE	VRE 1-year mortality 9/25 (36.0%)
Dubler et al.	2020	Germany	Retrospective, single centre, observational study	177 liver transplant recipients between January 2006 – December 2016 who had an <i>E. faecium</i> bacteraemia	VRE	VRE 30-day mortality 6/39 (15.4%) VRE 90-day mortality 15/39 (38.5%) Non-VRE 30-day mortality 15/138 (10.9%) Non-VRE 90-day mortality 43/138 (31.2%)

Mercuro et al.	2020	United States	Retrospective, single centre, cohort study	58 hospitalised SOT recipients (3 heart, 3 lung, 33 liver, 6 kidney, 10 intestinal, 3 multivisceral) with E faecium BSI between January 2013 – February 2019	VRE	VRE mortality - 13/41 (31.7%)
Kim et al.	2021	Korea	Retrospective, single centre, observational study	727 liver transplant recipients between January 2008 – December 2016	MRSA VRE 3GCR-E CRE CRAB CRPA	Pooled MDRO 90-day mortality 15/39 (38.5%)
Lee et al.	2022	US	Retrospective, multicentre, cohort study	117 liver transplant recipients (including 22 multivisceral) between January 2006 – December 2016	VRE	VRE 1-year mortality 29/108 (26.9%)
Anesi et al.	2023	United States	Retrospective, multicentre, cohort study	897 SOT recipients (69 episodes of heart transplant, 58 lung, 278 liver, 514 kidney, 27 pancreas) with an Enterobacterales BSI between 2005 – 2018	CRE	CRE 60-day mortality 33/70 (47.1%) Non-CRE 60-day mortality 102/827 (12.3%)
Min et al.	2023	Korea	Retrospective, single centre, nested case control study	1051 liver transplant recipients between September 2005 – December 2021	CRAB	CRAB 5-day mortality 17/29 (58.6%) CRAB 10-day mortality 19/29 (65.5%) CRAB 30-day mortality 19/29 (65.5%)

Abbreviations: 3GCR-E – Third-generation cephalosporin-resistant Enterobacterales, BSI – bloodstream infection, CRAB – carbapenem-resistant *Acinetobacter baumannii*, CRE – carbapenem-resistant Enterobacterales, CRKP – carbapenem-resistant *Klebsiella pneumoniae*, CRPA – carbapenem-resistant *Pseudomonas aeruginosa*, MDRO – multi-drug resistant organism/s, MRSA – methicillin-resistant *Staphylococcus aureus*, SOT – solid organ transplant, VRE – vancomycin-resistant *Enterococcus faecium*.